期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 138, 期 9, 页码 1911-1916出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2018.05.027
关键词
-
类别
资金
- Pfizer
- Sanofi
The advancement of genetic and preclinical studies has uncovered the mechanisms involved in the pathogenesis of alopecia areata (AA). The development of targeted therapies using small molecules blocking specific pathways for the treatment of AA is underway. By repurposing Food and Drug Administration-approved small molecule JAK inhibitors as treatments for AA, it has been demonstrated that JAK inhibitors can effectively reverse hair loss in patients with moderate to severe AA. In this review, we summarize and discuss the current preclinical and clinical studies on JAK inhibitors, as well as the prospects of using JAK inhibitors for the treatment of AA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据